Arca
Skip to content
Tools
Tools

SNCA: Alpha-synuclein

Neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release.

  • Drugs that act on it: 2
  • Approved: 0
  • In phases 1 to 3: 2
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on SNCA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2

Approved0

    Phase 30

      Phase 22

      • Prasinezumab
      • Cinpanemab

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        PrasinezumabPhase 2RocheAntibodyBinding agentAlpha-synuclein binding agent4
        CinpanemabPhase 2BiogenAntibodyInhibitorAlpha-synuclein inhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
        A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseasePrasinezumabPhase 3RecruitingHoffmann-La RocheSep 15, 2025
        Prevent Cognitive Decline in GBA-associated Parkinson's DiseasePrasinezumabPhase 2RecruitingUniversity Hospital TuebingenJul 8, 2025
        A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseasePrasinezumabPhase 2Active, not recruitingHoffmann-La RocheMar 2, 2021
        A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseasePrasinezumabPhase 2Active, not recruitingHoffmann-La RocheApr 4, 2017

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Late-onset Parkinson disease0.79
        • Young-onset Parkinson disease0.77
        • Parkinson disease0.76
        • Lewy body dementia0.74
        • AL amyloidosis0.46
        • REM sleep behavior disorder0.38
        • Parkinsonian-pyramidal syndrome0.37
        • Benign chondrogenic neoplasm0.27

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL6152, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P37840, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.